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Abstract
Background: Information extraction from microarrays has not yet been widely used in diagnostic or prognostic
decision-support systems, due to the diversity of results produced by the available techniques, their instability on
different data sets and the inability to relate statistical significance with biological relevance. Thus, there is an urgent need
to address the statistical framework of microarray analysis and identify its drawbacks and limitations, which will enable
us to thoroughly compare methodologies under the same experimental set-up and associate results with confidence
intervals meaningful to clinicians. In this study we consider gene-selection algorithms with the aim to reveal inefficiencies
in performance evaluation and address aspects that can reduce uncertainty in algorithmic validation.
Results: A computational study is performed related to the performance of several gene selection methodologies on
publicly available microarray data. Three basic types of experimental scenarios are evaluated, i.e. the independent test-
set and the 10-fold cross-validation (CV) using maximum and average performance measures. Feature selection methods
behave differently under different validation strategies. The performance results from CV do not mach well those from
the independent test-set, except for the support vector machines (SVM) and the least squares SVM methods. However,
these wrapper methods achieve variable (often low) performance, whereas the hybrid methods attain consistently higher
accuracies. The use of an independent test-set within CV is important for the evaluation of the predictive power of
algorithms. The optimal size of the selected gene-set also appears to be dependent on the evaluation scheme. The
consistency of selected genes over variation of the training-set is another aspect important in reducing uncertainty in the
evaluation of the derived gene signature. In all cases the presence of outlier samples can seriously affect algorithmic
performance.
Conclusion: Multiple parameters can influence the selection of a gene-signature and its predictive power, thus possible
biases in validation methods must always be accounted for. This paper illustrates that independent test-set evaluation
reduces the bias of CV, and case-specific measures reveal stability characteristics of the gene-signature over changes of
the training set. Moreover, frequency measures on gene selection address the algorithmic consistency in selecting the
same gene signature under different training conditions. These issues contribute to the development of an objective
evaluation framework and aid the derivation of statistically consistent gene signatures that could eventually be correlated
with biological relevance. The benefits of the proposed framework are supported by the evaluation results and
methodological comparisons performed for several gene-selection algorithms on three publicly available datasets.
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Background
Modern biological and biomedical research has been
challenged by the relatively new high-throughput meth-
ods of genomic, proteomic and metabolomic analysis [1],
such as DNA microarrays that allow the simultaneous
measurement of the expression of every gene in a cellular
genome. Two of the fundamental tasks in this area are the
identification of differentially expressed genes between
two or more conditions and the selection of a subset of
features (genes) with the best predictive accuracy for a cer-
tain classifier [2]. Various statistical methods for the anal-
ysis of microarray data exist, however data derived from
these methods are complex, hard to reproduce and
require expedient statistical analysis to minimize errors
and avoid bias.
Despite the plethora of methods that have been devel-
oped for information extraction from microarrays, such
information has not yet been widely used in diagnostic or
prognostic decision-support systems [3]. This is partly due
to the inconsistency of the derived results [4] and the dif-
ferent properties of various data sets [5-8]. For example, to
correctly distinguish the two types of leukemia, Golub et
al. [9] used a filter method and succeeded to derive a 50-
gene signature, whereas Guyon et al. [10] applied a wrap-
per method in combination with SVM on the same data
set and succeeded to derive an 8-gene signature.
Many studies have addressed the different issues involved
in data analysis from different microarray studies [11-14].
Here we briefly mention some of those, namely the exper-
imental platform used, the design of the study, the nor-
malization techniques employed or even the different
properties of the data distribution [5,10,15]. Also, from
the point of the statistical analysis of the data, different
study outcomes can be due to the different algorithms
used, the improper use of validation techniques and the
optimization techniques for the prediction model.
Additionally, various statistical issues can potentially
affect the results of a study. For example, the bootstrap-
ping strategy for the generation of random folds for train-
ing and testing is an issue of particular importance for
performance comparison of gene selection approaches.
Moreover, cross-validation (CV) can induce a certain bias
due to mixing of training and testing samples [16]. Leave-
one-out CV derives over-optimistic estimates, while three-
fold CV split may lead to a small number of training sam-
ples and hence the possibility of overtraining [17]. The
low performance of hard-margin SVM in [5] as compared
to [10] on the independent test-sets may be partially
attributed to such overtraining. Stratified re-sampling of
data may be used to maximize the power of comparison
among methods [18], but it can still modify the prior data
distributions leading to changes in performance esti-
mates. Similarly, random data splits often induce bias in
case-specific considerations because they randomly
exclude samples from the training or the testing process
[19,20]. Thus, there is a need to consider issues of influ-
ence in algorithmic performance and associate results
with confidence intervals meaningful to clinicians, in
order to thoroughly compare methodologies under the
same experimental and methodological set-up [16,20-
22].
Objectives of the study
Through our study we aim to reveal shortcomings in the
evaluation of gene selection approaches and address
methodological issues that may lead to more objective
evaluation schemes. Furthermore, we consider sample-
specific effects on the performance and stability of predic-
tion algorithms. For that purpose, we have selected three
well known publicly available data sets, namely the Van't
Veer et al. [23], the Golub et al. [9] and the Alon et al. [15]
data sets. Further details about the data sets used are given
in the following section.
Our ultimate objective, besides presenting and highlight-
ing the advantages and disadvantages of the tested meth-
odologies, is to explore fundamental characteristics in the
analysis of microarray data sets and identify methodolog-
ical aspects that may influence the evaluation of algo-
rithms. As a performance validation scheme we consider
ten-fold CV repeated ten times, i.e. 100 iterations in total.
It is worth recalling that CV with multiple gene-sets or dif-
ferent splits of data sets always presents some bias threats
[16,24]. In order to relieve such biases we consider testing
on an independent test-set at each step of the recursive
validation process. Finally, in order to avoid bias due to
the classification model, we estimate its parameters
through optimization on the independent test-set.
Results
Data sets
Three well known and publicly available data sets first
published at, [9,15] and [23] were considered. For the first
data set genes were hybridized using two-color arrays,
whereas for the other two one-color arrays were used. The
lists of genes, after platform-specific handling of the data,
were used as suggested by the corresponding authors.
Thus, platform specific effects were not considered.
The breast cancer (BC) data set [23] contains 24,481 genes
and 78 samples on the training set, 34 of which are char-
acterized positive and 44 negative accordingly to the pres-
ence or not of a relapse within a period of five years. 293
genes expressing missing information for all 78 patients
were removed and the remaining 13,604 missing values
were substituted using Expectation Maximization (EM)
imputation [25]. This set is used either as a training set orBMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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for the design of the CV trials and the specification of the
bootstrap training and testing subsets. The independent
test-set consists of 19 samples, 7 negative and 12 positive.
The leukemia data set in [9] consists of 38 bone marrow
samples obtained from acute leukemia patients at the
time of diagnosis. The data set is divided into 27 samples
of acute lymphoblastic leukemia (ALL) and 11 samples of
acute myeloid leukemia (AML). Data was analyzed using
an Affymetrix arrays which contained 7,129 human genes.
The independent test set consists of 34 samples (20 ALL
and 14 AML).
The colon cancer (CC) data set in [15] consists of 40
tumour and 22 normal colon tissue samples analyzed
with Affymetrix oligonucleotide array complementary to
more than 6,500 human genes. 2,000 genes were consid-
ered as suggested by [15] based on their minimal intensity
across samples. To create the training set, 28 tumour and
16 normal samples were randomly selected, while the
remaining samples constituted the independent set.
Data set analysis
To highlight differences between the three data sets, a
three-dimensional principal component analysis (PCA)
depicted in Figure 1 was performed, which could assist us
in estimating a decision boundary. Such an analysis
revealed that the BC data set perhaps demonstrates the
highest degree of overlap between the two classes. CC data
set appears to be more separable than BC, while the leuke-
mia data set appears to be most easily distinguishable.
Design of experimental scenarios
Three basic types of experimental scenarios are conducted
in order to estimate the performance of tested methodol-
ogies:
￿ In the independent test-set scenario the algorithms are
trained using the complete training set together with back-
ward feature elimination process. Thus, a varying number
of genes are recursively eliminated until 100 surviving
genes are left and subsequently one gene is eliminated
from this point onwards [26]. At each stage of the elimi-
nation process, the classifier is trained on the training-set
using the selected set of genes, while its performance with
respect to accuracy is measured on the independent test-
set using the same set of genes. Finally, the minimal set of
genes which achieves the maximum classification accu-
racy and classifies perfectly the training-set is the final set
of marker genes with the corresponding maximum accu-
racy performance on the independent test-set. Here, we
also measure the Q-statistic score [27] to investigate the
level of gene differentiation among the classes of interest
and gene correlation with the disease outcome. This sce-
Principal component analysis Figure 1
Principal component analysis. Three-Dimensional Princi-
pal Component Analysis (PCA) on the three examined data 
sets reveals that breast cancer (A) demonstrates the largest 
degree of overlap between the two classes, with colon can-
cer (C) coming next and leukemia (B) being the easiest one 
in locating a decision boundary.
 (A) Breast cancer
(B) Leukemia 
(C) Colon Cancer BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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nario is essentially used for the estimation of algorithmic
parameters and of the size of gene signature with high
accuracy and good generalization on the independent
test-set.
￿ The maximum performance on a 10-fold CV scenario is used
to access optimal algorithmic performance under CV, sim-
ilar to the GEMS approach [28,29]. The initial set of train-
ing samples is randomly partitioned into ten groups. Each
group, denoted by fold for the rest of this paper, is itera-
tively used for testing, whereas the remaining folds are
used for the training of the algorithms. Thus, 90% of the
set is used for training purposes, while the remaining 10%
is used as the test-set. This CV process is repeated ten times
resulting in total to 100 test iterations, i.e. 10(folds)  ×
10(splits per fold). Each iteration proceeds independently
with gene selection according to the previous cut-off strat-
egy. The maximum performance for each run on the test-
ing subset is reported along with the corresponding
number of surviving genes. Finally, we report the grand
average of maximum accuracies along with the corre-
sponding number of gene-sets and confidence intervals
(CIs) on classification accuracy.
￿ The average performance on a 10-fold CV scenario operates
with fixed parameters of the tested algorithms and termi-
nates at a fixed number of selected genes determined by
the independent test-set scenario. Feature selection is per-
formed within each run of the CV process in order to
avoid overestimation of the prediction accuracy [30,31].
Testing is performed on the test folds of CV, but also on
the common independent test-set. In this scenario, aver-
age accuracy measures are estimated in an attempt to
reduce random correlation effects and increase the confi-
dence that the test measurements reflect the true predic-
tive ability of each method. CIs on classification accuracy
are used, where appropriate, as a stability measure reveal-
ing the variation in the performance of the tested method-
ologies. Furthermore, we report the number of commonly
selected genes as an indicator of the stability of the tested
methodologies over different training-sets. The frequency
of gene appearance in classification rules has also been
used by [19,20] in order to control the rate of genes
selected at random.
Except from measures on the overall population used in
CV, we also resort to case-specific considerations to
increase the clinical relevance of algorithmic accuracy esti-
mates. The accuracy, usually measured over many itera-
tions, cannot evaluate the efficiency of the algorithm to
correctly classify individual cases. Thus, high accuracy
may be due to correct classification of different cases in
each run, providing an overall high score for this measure
even though single cases may not be correctly classified in
most runs of the algorithm. However, when considering
clinical evaluation of a new case, it is important to have
high confidence in the correct categorization of the indi-
vidual subject based on the training examples. For that
reason it is essential to consider per subject accuracy meas-
ures, which assist in increasing the efficiency of the algo-
rithm to correctly identify new cases with similar
attributes, as those involved in the training set. Through
such measures, we can also consider the stability and gen-
eralization ability of each algorithm on the basis of per
subject success or failure, as well as account for the influ-
ence of entire-sample measurement errors on the estima-
tion of the prediction power of each method. All those
measures are presented along with appropriate CIs
derived from the CV process.
For the effective evaluation of measures a performance
profile of each algorithm is computed, i.e. a table with col-
umns reflecting all subjects and rows indicating the CV
runs. For each run (row), the table captures a binary value
for each case (column) if that subject is in the test-set of
the run. This value indicates the prediction success for that
specific subject on the specific run. In this form, the aver-
age of per subject accuracies over all runs reflects the per
subject accuracy of the algorithm, whereas the average of
per run accuracies over all testing cases reflects its per run
accuracy. The notation of such accuracy measures is spec-
ified in subsequent sections.
Three classes of methods have been chosen for selecting
the number of genes with best performance in sample
classification, namely filter, wrapper and hybrid methods.
Filter and wrapper methods have been extensively used
for gene selection, whereas hybrid methods have also
shown considerable success by combining the advantages
of the previous classes [26]. Filter methods reveal the dis-
criminatory ability of each gene by employing various cri-
teria such as the Fisher's criterion which is also used in the
present study. Wrapper methods traditionally employ
SVM classifiers in a recursive feature elimination (RFE)
mode to reveal the prediction ability of groups of genes,
but other (rather simple) predictors have also been tested.
In our study wrapper methods were employed via five
algorithms, and in particular the RFE based on Linear
Neuron Weights using Gradient Descent (RFE-LNW-GD),
the RFE based on Support Vector Machines (RFE-SVM),
the RFE based on Least Square Support Vector Machines
(RFE-LSSVM), the RFE based on Ridge Regression (RFE-
RR) and the RFE based on Fisher's Linear Discriminant
Analysis (RFE-FLDA). Hybrid methods are examined via
RFE based on Linear Neuron Weights (RFE-LNW1, RFE-
LNW2), and RFE based on Fisher's ratio of Support Vec-
tors using a 7 Degree polynomial Kernel (RFE-FSVs-7DK).
More details can be found in Methods section.BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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Maximum Performance Results
Independent Test-set
The maximum performance results of filter, wrapper and
integrated schemes on the independent test-set are pre-
sented in Tables 1, 2 and 3. Accuracy measures, as defined
in Methods section, are presented along with sensitivity
and specificity measures, reflecting the ability to correctly
classify good and bad prognosis, respectively. The Q-sta-
tistic measure and the number of selected genes for
achieving maximum performance on the independent
test-set are also assessed.
We first notice that for the BC data set (Table 1) RFE-FSVs-
7DK is the best accuracy performer, achieving the highest
success rate of 95% (only one sample is misclassified)
with 73 genes selected. It also achieves the highest specif-
icity measure with adequately high sensitivity. Noticeable
is the fact that the same method achieves a relatively high
statistical significance score, close to that of the filter
method, which is the highest performer of the Q-statistic.
RFE-LNW1 also demonstrates noticeable performance
both in terms of accuracy and statistical significance.
Alternatively, the RFE-LNW2 and filter method have sim-
ilar results indicating that by using a relatively low learn-
ing rate RFE-LNW approach converges to the result of the
pure filter method. From the wrapper methods, RR and
FLDA achieve high accuracy with better sensitivity than
specificity values.
For the leukemia dataset (Table 2) most algorithms
(except the wrapper RR and FLDA methods) attain higher
accuracy than in breast cancer (Table 1), which is justified
due to its well defined classes. The specificity of all meth-
ods is remarkably high. Nevertheless, this is not true for
sensitivity with only LNW, SVM and hybrid methods
achieving scores over 86%. Moreover, the hybrid methods
preserve good values of the Q-statistic, slightly better than
the filter method, revealing high discrimination over the
selected gene signatures. The wrapper methods in general
reflect lower values of the Q-statistic metric, implying
weaker discrimination of genes amongst the classes of
interest, and low correlation between gene expression
level and prediction outcome. The wrapper LNW and SVM
methods reflect better performance than the filter
method.
For the CC data set (Table 3) all methods (except the
wrapper RR) achieve more than 88% accuracy, with wrap-
per LNW-GD, LSSVM and hybrid LNW1 and RFE-FSVs
being the best performers, achieving also the highest sen-
sitivity rate. We point out the inferior performance of the
wrapper RR method compared to previous results indicat-
ing that the specific algorithm is highly affected by differ-
ences in the experimental settings, as it is also pointed out
in the leukemia data set. The sensitivity achieved by all
methods (except RR) is remarkably high while at the same
time, the hybrid methods preserve higher values of the Q-
Statistic compared to the wrapper schemes and close or
better (RFE-LNW2) than the filter method. An exception
is the wrapper LNW-GD which achieves a high score close
to the filter method as well. Overall, the hybrid schemes
preserve top performance amongst the tested methods for
all data sets. We may also infer that the wrapper RR and
FLDA methods are most affected by the differences in the
experimental settings.
Cross-validation
The results of this experimental scenario concerning BC,
leukemia and CC data sets are presented in Tables 4, 5, 6,
respectively. We can observe that filter method perform
well in all cases, resulting in higher accuracy and smaller
CIs. There is a similar tendency for the hybrid methods for
all data sets. For the wrapper methods, however, the per-
formance varies depending on the data set. Furthermore,
the wrapper methods derive wider CIs in the more com-
plex set of breast cancer, indicating larger variation of
results throughout the CV iterations.
For the CV testing of BC, the wrapper schemes exhibit less
accuracy and stability, yielding larger CIs. The inferior
Table 1: Maximum Performance results on the independent test-set under the first testing scenario, Van't Veer et al. [23] (breast 
cancer) data set.
Filter Method Wrapper Methods Hybrid Methods
Criterion Fisher's Ratio RFE-LNW-GD RFE-SVM RFE-LSSVM RFE-RR RFE-FLDA RFE-LNW1 RFE-LNW2 RFE-FSVs-7DK
Accuracy 0.74 0.84 0.79 0.79 0.89 0.89 0.89 0.74 0.95
Sensitivity, 
Specificity
0.75, 0.71 0.83, 0.86 0.75, 0.86 0.83, 0.71 1.0, 0.71 0.92, 0.86 0.92, 0.86 0.75, 0.71 0.92, 1.00
Q-Statistic 
quality measure
135.78 81.21 52.12 12.91 82.60 42.58 99.05 131.78 112.43
Number of 
genes selected
61 22 32 45 7 28 44 64 73BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
Page 6 of 22
(page number not for citation purposes)
accuracy of wrapper methods is primarily attributed to
their lower sensitivity. Alternatively, for the leukemia data
set (Table 5) most wrapper schemes (except RR) increase
their maximum accuracy measures in CV compared to
independent test-set scenario, whilst attaining good sensi-
tivity and specificity scores. In fact, the FLDA scheme
reaches the maximum accuracy followed by LSSVM and
LNW-GD, but in this case the accuracy performance of all
methods is comparably high.
For the CC data set (Table 6), even though all methods
decrease their performance in comparison to leukemia
data set, they still exhibit a high accuracy level ranging
from 83% to 91%. We point out the increase in the per-
formance of the wrapper RR method, compared to the
previous evaluation procedure (independent test-set sce-
nario), indicating once more that the method is strongly
influenced by the different experimental scenarios. As in
the case of the leukemia data set, a decrease in algorithmic
performance is observed when compared to the inde-
pendent test-set scenario. The wrapper LSSVM and hybrid
FSVs and LNW1 are the top performers, with LSSVM
achieving a higher sensitivity rate among the three. Gener-
ally speaking, the wrapper methods (with the exception of
LSSVM and FLDA methods) have higher CIs than the
hybrid and the filter methods, indicating higher variation
of results throughout the CV iterations, as was also
expressed in BC data. Moreover, hybrid methods tend to
select less number of genes than both the filter and wrap-
per approaches.
Considering these results, we may conclude that the per-
formance of pure wrapper methods is more affected by
the experimental conditions with performance measures
varying over cross-experimental evaluation. Furthermore,
wrapper methods appear to benefit from integrating
appropriately adapted filtering criteria (hybrid
approaches) into their learning procedure. Such integra-
tion would lead to a more stable performance by preserv-
ing high levels of statistical significance under both tested
scenarios and experimental frameworks.
Overall, the evaluation (or ranking) of algorithms
changes under a cross experiment evaluation or when
considering different evaluation schemes such as CV or
single-step evaluation with testing on an independent
Table 3: Maximum performance results on the independent test-set under the first testing scenario Alon et al. [15] (colon cancer) 
data set.
Filter 
Method
Wrapper Methods Hybrid Methods
Criterion Fisher's Ratio RFE-LNW-GD RFE-SVM RFE-LSSVM RFE-RR RFE-FLDA RFE-LNW1 RFE-LNW2 RFE-FSVs-7DK
Accuracy 0.89 0.94 0.89 0.94 0.67 0.89 0.94 0.89 0.94
Sensitivity, 
Specificity
1.00, 0.67 1.00, 0.83 0.92, 0.83 1.00, 0.83 0.58, 0.83 1.00, 0.67 1.00, 0.83 1.00, 0.67 1.00, 0.83
Q-Statistic 
quality measure
128.39 127.46 72.74 50.33 33.68 33.76 92.83 128.43 103.39
Number of 
genes selected
16 9 8 11 10 8 10 16 25
Table 2: Maximum Performance results on the independent test-set under the first testing scenario Golub et al. [9] (leukemia) data set.
Filter 
Method
Wrapper Methods Hybrid Methods
Criterion Fisher's Ratio RFE-LNW-GD RFE-SVM RFE-LSSVM RFE-RR RFE-FLDA RFE-LNW1 RFE-LNW2 RFE-FSVs-7DK
Accuracy 0.91 0.94 0.94 0.85 0.82 0.82 0.94 0.94 0.94
Sensitivity, 
Specificity
0.79, 1.00 0.86, 1.00 0.86, 1.00 0.79, 0.90 0.57, 1.00 0.57, 1.00 0.93, 0.95 0.86, 1.00 0.86, 1.00
Q-Statistic 
quality measure
230.76 210.8 185.38 16.42 140.00 243.06 241.99 254.67 217.23
Number of 
genes selected
61 7 4 3 3 7 2 2 7 0 1 2BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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test-set. The CV scheme appears to give a certain (positive
or negative) bias to all algorithms. Furthermore, the opti-
mal size of the selected gene-set appears to be dependent
on the evaluation scheme. The CV scheme driven by its
various training sets can lead to a quite skewed distribu-
tion of performance estimates for various sizes of selected
gene signatures. Thus, the final size of signature attaining
maximum performance within the multiple iterations of
CV can be easily affected by several random effects. In
essence, factors of bias in maximum CV performance
include the small size correlation effect and the intermix-
ing of samples within the training and test-set. Similar
criticism on maximum or ranked performance schemes
has been reported by other studies [24].
From this section it is obvious that the ranking of methods
is highly dependent on the evaluation strategy. For a more
objective comparison of algorithms, we consider in the
next section the average performance of algorithms at a
certain cut-off point on the number of surviving genes.
Thus, the size of the gene signature is specifically chosen
for each algorithm based on its best performance on the
independent test-set (Tables 1, 2, 3), in order to test how
well algorithms will perform with new cases.
Average Performance Results on Cross-validation
The average per run and per subject accuracies (accR and
accP) along with their standard deviations (stds) are tabu-
lated in Tables 7, 8, 9. The measures of sensitivity and spe-
cificity are also reported on the basis of per run tests for
the test population in CV and in the independent sets. The
algorithms achieving the highest accuracy as well as the
lowest stds are highlighted with bold figures. The last row
of those tables presents the overall measures on all sam-
ples tested (CV test set plus the independent test set) and
reflects the overall performance ability of each algorithm.
When considering the same population for testing, e.g.
the independent test-set, the two measures, accR
t (per run)
and  accP
t (per subject), obtain identical values. Notice,
however that we expect a difference in stds due to the dif-
ferent reference cohorts, i.e. the different runs and subjects
used.
The overall accuracy measures along with their CIs are
graphically depicted in Figures 2, 3, 4. Furthermore, Fig-
Table 5: Maximum Performance results on cross validation under the second testing scenario; 10-fold cross validation Golub et al. [9] 
(leukaemia) data set.
Filter 
Method
Wrapper Methods Hybrid Methods
Criterion Fisher's Ratio RFE-LNW-GD RFE-SVM RFE-LSSVM RFE-RR RFE-FLDA RFE-LNW1 RFE-LNW2 RFE-FSVs-7DK
Accuracy 0.99 0.99 0.99 0.99 0.48 0.997 0.96 0.99 0.98
Sensitivity, 
Specificity
0.95, 1.00 1.00, 0.99 0.95, 1.00 0.98, 0.99 1.00, 0.31 0.99, 1.00 0.90, 0.98 0.95, 1.00 0.91, 1.00
Confidence 
Interval
0.1 0.08 0.1 0.09 0.4 0.05 0.17 0.1 0.12
Number of 
genes selected
45 4 3 0 6 5 4 4 3
Table 4: Maximum Performance results on cross validation under the second testing scenario; 10-fold cross validation Van't Veer et al. 
[23] (breast cancer) data set.
Filter 
Method
Wrapper Methods Hybrid Methods
Criterion Fisher's Ratio RFE-LNW-GD RFE-SVM RFE-LSSVM RFE-RR RFE-FLDA RFE-LNW1 RFE-LNW2 RFE-FSVs-7DK
Accuracy 0.88 0.78 0.76 0.75 0.74 0.75 0.82 0.88 0.85
Sensitivity, 
Specificity
0.83, 0.90 0.77, 0.81 0.68, 0.80 0.68, 0.80 0.68, 0.77 0.69, 0.80 0.74, 0.88 0.82, 0.90 0.84, 0.86
Confidence 
Interval
0.21 0.27 0.29 0.28 0.26 0.27 0.25 0.21 0.21
Number of 
genes selected
35 26 33 36 39 28 35 33 21BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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ures 5, 6, 7 show the per subject accuracy and the CIs of
classification accuracy for the independent test-sets. Note
the large variability among sample accuracies in the case
of BC (Figure 5) and the relative consistency of estimation
throughout the tested subjects in the case of leukemia
(Figure 6). Concerning the consistency of algorithms in
terms of selected gene signatures over the CV iterations,
the consistency (or gene overlap) index is tabulated in
Table 10 for all tested algorithms. With the exception of
the LSSVM and RFE-LNW-GD methods, wrapper methods
appear to select different genes per iteration, resulting in
quite small indices. Filter, as well as hybrid, methods yield
good consistency based on their high frequencies of
selecting the same genes throughout CV iterations. Never-
theless, we should stress our belief that in a further devel-
opment stage we need to also associate the statistical
results with the biological meaning of selected gene signa-
tures.
Comparing the performance results, we first notice that
the average accuracy measures (Tables 7, 8, 9) are signifi-
cantly smaller than their maximum counterparts in the
Table 7: Average performance measures under the third testing scenario, sample mean and std of accuracies Van't Veer et al. [23] 
(breast cancer) data set.
Filter 
Method
Wrapper Methods Hybrid Methods
Method Fisher's Ratio RFE LNW-GD RFE-SVM RFE-LSSVM RFE-RR RFE-FLDA RFE-LNW1 RFE-LNW2 RFE-FSVs-7DK
Number of genes 
selected
61 22 32 45 7 28 44 64 73
Per Subject AccP-
CV
0.744 0.612 0.580 0.644 0.509 0.573 0.612 0.788 0.668
Std(P)-CV 0.320 0.306 0.354 0.385 0.267 0.276 0.352 0.254 0.387
Per Subject AccP-
Test
0.660 0.719 0.584 0.658 0.659 0.614 0.753 0.669 0.735
Std(P)-Test 0.230 0.277 0.294 0.358 0.173 0.240 0.236 0.217 0.221
Per Run AccR-CV 0.708 0.587 0.570 0.598 0.514 0.546 0.621 0.708 0.653
Sensitivity, 
Specificity
0.66, 0.70 0.53, 0.63 0.54, 0.61 0.43, 0.61 0.50, 0.58 0.52, 0.56 0.55, 0.67 0.67, 0.73 0.64, 0.63
Std(R)-CV 0.174 0.172 0.187 0.175 0.196 0.199 0.156 0.158 0.164
Per Run Test 
AccR-Test
0.660 0.719 0.584 0.658 0.659 0.614 0.753 0.669 0.735
Sensitivity, 
Specificity
0.65, 0.64 0.70, 0.75 0.63, 0.59 0.55, 0.69 0.69, 0.50 0.65, 0.55 0.79, 0.68 0.67, 0.67 0.76, 0.55
Std(R)-Test 0.102 0.099 0.085 0.077 0.102 0.116 0.073 0.104 0.079
Per Run All AccR-
Overall
0.673 0.684 0.580 0.642 0.620 0.596 0.717 0.680 0.713
Std(R)-Overall 0.091 0.083 0.080 0.080 0.098 0.105 0.068 0.087 0.077
Table 6: Maximum performance results under the second testing scenario; 10-fold cross validation Alon et al. [15] (colon cancer) data set.
Filter 
Method
Wrapper Methods Hybrid Methods
Criterion Fisher's Ratio RFE-LNW-GD RFE-SVM RFE-LSSVM RFE-RR RFE-FLDA RFE-LNW1 RFE-LNW2 RFE-FSVs-7DK
Accuracy 0.90 0.87 0.87 0.91 0.83 0.89 0.91 0.89 0.91
Sensitivity, 
Specificity
0.92, 0.88 0.89, 0.85 0.92, 0.79 0.97, 0.81 0.77, 0.91 0.93, 0.84 0.93, 0.88 0.93, 0.84 0.93, 0.89
Confidence 
Interval
0.25 0.29 0.29 0.22 0.31 0.26 0.22 0.26 0.24
Number of 
genes selected
16 17 16 22 19 14 10 15 12BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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previous section (Tables 1, 2, 3). Recall that in the present
scenario each algorithm is applied with fixed parameters
for all CV iterations and terminates at a fixed number of
surviving genes, which is specified by its point of maxi-
mum performance on the independent test-set (Tables 1,
2, 3). This scenario is much closer to a clinical testing and
validation set-up, so that these results, even though infe-
rior, reflect more closely the actual potential of algorithms
in clinical prediction. It can also be observed that, simi-
larly to the maximum performance measures, the average
accuracy of the CV samples differs from that of the inde-
pendent test samples, either on a per run or a per subject
basis (Tables 7, 8, 9). This deviation is consistent for all
three datasets. Furthermore, all methods demonstrate
consistently lower stds when tested on the independent
test-set than on the testing fold of the CV set for the BC
and CC data sets (Tables 7 and 9). This is a direct conse-
quence of the fact that in the former case the testing set is
kept constant across all iterations (fixed independent test-
set). Nevertheless, this performance is reversed for the
leukemia data set (Table 8), which is possibly due to sta-
tistical differences in the distributions of the training (CV)
and testing samples and implies insufficient training of
the algorithms.
Considering the results over all testing samples (Tables 7,
8 and 9), which we consider as good estimates of the true
algorithmic performances (golden standard for compari-
son), we notice that they are more closely approximated
by the results of the independent test-set than by those of
CV test folds. More specific comparisons on algorithmic
performance are summarized in the following sections.
Filter and Wrapper methods
All methods reflect a positive or negative bias on the accu-
racy estimates of the CV set over those of the independent
test-set and the overall testing set, depending on the data
set. The baseline filter method for all data sets derives
good accuracy on the CV tests (Tables 7, 8, 9), which is in
accordance to the results of [6]. In fact, its accuracy on CV
tests is higher than all wrapper methods tested. Neverthe-
less, such a good performance is not sustained on the
independent test-set (Tables 7, 8, 9). Furthermore, the std
indices for the leukemia data set achieve their lowest val-
ues for the filter method, but such algorithmic stability is
dependent on the data set.
The wrapper scheme based on the linear neuron (LNW-
GD) results in better accuracy on the independent test-set,
either on a per run or per subject basis (Tables 7 and 9) for
Table 8: Average performance measures under the third testing scenario, sample mean and std of accuracies Golub et al. [9] 
(leukaemia) data set.
Filter 
Method
Wrapper Methods Hybrid Methods
Method Fisher's Rattio RFE-LNW-GD RFE-SVM RFE-LSSVM RFE-RR RFE-FLDA RFE-LNW1 RFE-LNW2 RFE-FSVs-7DK
Number of 
genes selected
61 7 4 3 3 7 2 2 7 0 1 2
Per Subject 
Acc(P)-CV
0.95 0.94 0.88 0.73 0.42 0.89 0.93 0.97 0.93
Std(P)-CV 0.15 0.20 0.21 0.40 0.39 0.16 0.23 0.16 0.21
Per Subject 
Acc(P)-Test
0.87 0.86 0.82 0.78 0.70 0.81 0.91 0.88 0.85
Std(P)-Test 0.25 0.28 0.30 0.31 0.19 0.23 0.2 0.26 0.28
Per Run 
Acc(R)-CV
0.96 0.94 0.89 0.75 0.39 0.89 0.93 0.97 0.94
Sensitivity, 
Specificity
0.87, 0.99 0.89, 0.96 0.65, 0.97 0.47, 0.85 0.99, 0.19 0.74, 0.94 0.88, 0.95 0.89, 0.99 0.69, 0.98
Std(R)-CV 0.09 0.107 0.14 0.20 0.12 0.16 0.14 0.09 0.11
Per Run Test 
Acc(R)-Test
0.87 0.86 0.82 0.78 0.70 0.81 0.91 0.88 0.85
Sensitivity, 
Specificity
0.69, 1.00 0.67, 0.99 0.58, 0.98 0.62, 0.90 0.57, 0.79 0.60, 0.95 0.87, 0.94 0.72, 0.99 0.52, 0.95
Std(R)-Test 0.03 0.05 0.07 0.06 0.11 0.08 0.04 0.05 0.05
Per Run All 
Acc(R)-Overall
0.88 0.87 0.82 0.78 0.67 0.82 0.91 0.89 0.86
Std(R)-Overall 0.04 0.05 0.06 0.05 0.10 0.08 0.04 0.04 0.05BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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Table 9: Average performance measures under the third testing scenario; sample mean and std of accuracies Alon et al. [15] (colon 
cancer) data set.
Filter 
Method
Wrapper Methods Hybrid Methods
Method Fisher's Ratio RFE-LNW-GD RFE-SVM RFE-LSSVM RFE-RR RFE-FLDA RFE-LNW1 RFE-LNW2 RFE-FSVs-7DK
Number of 
genes selected
16 9 8 11 10 8 10 16 25
Per Subject 
Acc(P)-CV
0.77 0.70 0.71 0.74 0.65 0.73 0.74 0.74 0.75
Std(P)-CV 0.32 0.31 0.34 0.40 0.30 0.29 0.31 0.32 0.32
Per Subject 
Acc(P)-Test
0.82 0.79 0.80 0.90 0.67 0.79 0.80 0.81 0.85
Std(P)-Test 0.26 0.26 0.26 0.23 0.22 0.22 0.29 0.25 0.24
Per Run 
Acc(R)-CV
0.77 0.70 0.72 0.72 0.66 0.74 0.75 0.75 0.76
Sensitivity, 
Specificity
0.81, 0.73 0.75, 0.63 0.80, 0.60 0.86, 0.51 0.60, 0.76 0.79, 0.66 0.76, 0.75 0.8, 0.68 0.77, 0.73
Std(R)-CV 0.19 0.19 0.18 0.17 0.19 0.18 0.19 0.20 0.19
Per Run Test 
Acc(R)-Test
0.82 0.79 0.80 0.90 0.67 0.79 0.80 0.81 0.85
Sensitivity, 
Specificity
0.94, 0.58 0.88, 0.63 0.92, 0.58 0.98, 0.73 0.61, 0.80 0.88, 0.60 0.91, 0.58 0.93, 0.59 0.95, 0.64
Std(R)-Test 0.08 0.09 0.07 0.10 0.13 0.08 0.08 0.08 0.06
Per Run All 
Acc(R)-Overall
0.81 0.77 0.79 0.86 0.67 0.78 0.79 0.81 0.83
Std(R)-Overall 0.08 0.09 0.06 0.09 0.11 0.08 0.07 0.08 0.06
Table 10: Consistency index (average gene frequency) for the tested algorithms.
Method-Group Kategory Kategory Method Breast Cancer Leukemia Colon Cancer
Filter Method Fisher's ratio 0.64 0.74 0.80
Wrapper Methods RFE-LNW-GD 0.70 0.71 0.65
RFE-SVM 0.49 0.37 0.35
RFE-LSSVM 0.87 0.89 0.87
RFE-RR 0.18 0.06 0.30
RFE-FLDA 0.32 0.25 0.22
Hybrid Methods RFE-LNW1 0.53 0.63 0.55
RFE-LNW2 0.64 0.78 0.79
RFE-FSV-7DK 0.58 0.63 0.63BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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the more difficult BC and CC data sets. This is reversed for
the leukemia data set (Table 8), where the compact nature
of samples in each class forces its performance on CV test-
ing towards overestimated measures. Nevertheless, it
maintains reasonable performance on the overall test-set,
with balanced sensitivity and specificity.
Considering the BC data set and the other wrapper RFE
approaches on their average per run performance, we
observe that on the independent test-set (Table 7) RR and
FLDA perform better than SVM, which is in accordance to
the results of [8]. However, the SVM and its least squares
variant yield better specificity than the RR and FLDA
methods. This performance is reversed when considering
CV (Table 7). In this case, the performance of SVM is
slightly better than FLDA, which is in accordance to the
findings of [5]. For the leukemia data set (Table 8) the
SVM-based approaches perform better for both the inde-
pendent test-set and the CV approaches, with increased
specificity, but reduced sensitivity over the RR and FLDA
methods. This improvement is attributed to the character-
istic distribution of support vectors in the leukemia data
set, which expresses better class separability compared to
the BC data set [32]. Similarly for CC (Table 9), the SVM-
based approaches perform better than the other wrapper
methods, but now due to increased sensitivity. With the
exception of the excellent performance of the LSSVM on
the independent and the overall test-sets, the performance
of wrapper methods in colon cancer is in accordance to
the performance ranking for the other two data sets.
Despite its high performance in CC, the LSSVM method
expresses a large variation on the accuracy measures for
CV testing and the independent test-set, which may be
due to the particular selection of the independent test-set.
Notice that in this case the independent set was randomly
selected from the original data in [15], unlike the other
two data sets considered which supplied different inde-
pendent data sets. Furthermore, its increased performance
on the independent test-set is mainly due to its increased
sensitivity over all other algorithms (Table 9). The spo-
radic nature of its results is also verified by its rather low
performance on the other two data sets. Overall, for all
data sets the variation of results in wrapper methods is
quite large between the CV and the independent test-set
data sets, indicating a significant influence of the training
and/or testing sets on the performance of these algo-
rithms. In particular, the LSSVM achieves its best perform-
Performance evaluation in breast cancer Figure 2
Performance evaluation in breast cancer. Average 
cross validation performance and confidence intervals of 
algorithms for the breast cancer data set of [23].
Performance evaluation in leukaemia Figure 3
Performance evaluation in leukaemia. Average cross 
validation performance and confidence intervals of algo-
rithms for the leukemia data set of [9].
Performance evaluation in colon cancer Figure 4
Performance evaluation in colon cancer. Average cross 
validation performance and confidence intervals of algo-
rithms for the colon cancer data of [15].BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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Per-subject performance evaluation and confidence intervals in breast cancer Figure 5
Per-subject performance evaluation and confidence intervals in breast cancer. Average cross validation accuracies 
and confidence intervals per-subject, in the independent test-set of breast cancer data [23]. 19 subjects tested 100 times for 
the (a) filter, (b) wrapper SVM and (c) hybrid LNW1 algorithms.
(A) Filter 
(B) RFE-SVM 
(C) RFE-LNW1 BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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Per-subject performance evaluation and confidence intervals in leukaemia Figure 6
Per-subject performance evaluation and confidence intervals in leukaemia. Average cross validation accuracies and 
confidence intervals per-subject in the independent test-set for leukemia data of [9]. 34 subjects tested 100 times for the (a) fil-
ter, (b) wrapper SVM and (c) hyprid LNW1 algorithms.
 (A) Filter 
(B) RFE-SVM 
(C) RFE-LNW1 BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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Per-subject performance evaluation and confidence intervals in colon cancer Figure 7
Per-subject performance evaluation and confidence intervals in colon cancer. Average cross validation accuracies 
and confidence intervals per-subject in the independent test-set for colon cancer data [15]. 18 subjects tested 100 times for 
the (a) filter, (b) wrapper SVM and (c) hyprid LNW1 algorithms.
 (A) Filter 
(B) RFE-SVM 
(C) RFE-LNW1 BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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ance on colon cancer. On similar grounds, the RR method
performs relatively similar to the other wrapper methods
on breast cancer, but presents the worst performance on
the other two data sets. These results further highlight the
need for evaluating the ranking of wrapper algorithms on
a series of tests over different data sets. An additional
drawback for wrapper methods is the weak consistency of
the derived gene signatures between iterations, as reflected
by their low consistency index presented in Table 10. Only
the LSSVM approach attains exceptionally high consist-
ency index, indicating a consistent selection of genes, but
the selected gene signatures in most cases do not reflect
high prediction power. Hybrid and filter methods com-
bine relatively high consistency index with increased suc-
cess rate and more stable performance over the different
datasets.
Hybrid methods
Concerning the hybrid approaches, the FSV scheme is one
of the best two algorithms in BC and CC, with its perform-
ance being slightly inferior of other hybrid methods in the
leukemia data set. More specifically, for the BC and CC
case FSV succeeds high accuracy on either a per run or a
per subject base when testing the independent and the
overall test-set (Table 7 and 9). This performance slightly
drops relative to other hybrid methods in the case of
leukemia, where the CV scheme reflects highly overesti-
mated measures (Table 8). A possible reason for that is
that the optimal representation kernel (7 degree polyno-
mial) of the BC data set is also used for the leukemia and
CC data sets. A different kernel with better fit to the distri-
bution of the leukemia or CC data sets would further
improve the performance of this method.
The neural network-based algorithms (LNW1 and LNW2)
are amongst the best performers in BC and leukemia data
sets. The LNW2 algorithm exhibits highly optimistic esti-
mates in CV (Tables 7, 8), while its overall performance is
amongst the highest for leukemia. The LNW1 approach
yields good per run accuracies for these data sets, when
tested on either the independent test-set (Tables 7 and 8)
or the entire test-set (last row in Tables 7 and 8). It also
derives consistently small variances per run, reflecting
good stability properties as it appears to be less affected by
variation of the training and/or testing sets. The perform-
ance rank of LNW1 and LNW2 on CC drops slightly,
mainly due to the exceptional performance of the wrapper
LSSVM method. Nevertheless, all hybrid methods per-
form better than RFE-LSSVM on cross validation (Table
9), while they all achieve above 80% accuracy on the inde-
pendent test-set (Table 9) with the best performer being
the RFE-FSVs (85% average success rate).
Testing on all available samples (both sampling and inde-
pendent test-sets) through CV is regarded to be a more
unbiased test on algorithmic performance and is used as a
reference for comparison (Tables 7, 8, 9). Regarding such
overall performance results, the hybrid FSV approach
takes the lead in overall performance, followed by LNW1
and LNW2, with slight variations.
The performance of hybrid methods on the overall set is
closely matched by the results of testing on the independ-
ent test-set throughout the iterations, either on per run or
per subject basis, further emphasizing the necessity of an
independent test-set in evaluation procedures and the
utility of both performance and stability measures. These
hybrid methods also achieve relatively high consistency
index compared to wrapper methods (except the LSSVM)
as illustrated in Table 10. Thus, considering several aspects
of their performance, we may claim that the hybrid
approaches provide consistently good performance and
stability in the independent test-set, both on per run and
per subject basis.
Outlier Samples
Another important aspect of this work is the considera-
tion of the influence of noisy samples. Considering the
per subject stability (std measure) of algorithms in all
cases, we observe relatively increased values compared to
the per run measures (Tables 7, 8 and 9), which indicate a
quite large variability in the algorithmic estimates for
individual case depending on the training set. This is an
indication of problems caused by the limited training-set
used in the design of prediction models. Since the model
is designed with limited information from the feature
space, specific test samples may not fit well to its design
specifications. The variability for the independent test-set
is graphically presented in Figures 5, 6, and 7 for the base-
line filter, wrapper SVM and hybrid LNW1 approaches
and the three cases, respectively. An accuracy deviation on
specific samples is more severe in breast cancer and less
severe in leukemia, following the difficulty in class separa-
bility illustrated by the PCA analysis in Figure 1.
Further analyzing the BC case (Figure 5), we notice that
the performance of algorithms on test samples is variable,
with the exception of some samples on which the average
performance of all algorithms is quite low. These specific
samples are ID 37, 38, 54, 60 and 76 from the Van't Veer's
training-set, as well as sample ID 117 from the independ-
ent test-set. Generally, these samples cannot be well clas-
sified and can be characterized as outliers. When
excluding only these samples, the average performance
measures are significantly affected, as presented in Table
11. Comparing the corresponding measures in Tables 7
and 11, it becomes obvious that only a few outliers due to
measurement errors can drastically deteriorate the per-
formance of any prediction algorithm.BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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In a similar consideration for the leukemia data set (Fig-
ure 6), we may conclude that sample 31 is probably an
outlier since all methods examined fail to classify it. Fur-
thermore, for CC (Figure 7) we may suspect samples 3, 4
and 6 as outliers, since most methods fail to effectively
classify them. The identification and removal of such sam-
ples is of primary importance in algorithmic evaluation,
especially in the area of gene selection with sparsely cov-
ered data spaces. The identification scheme proposed here
is an alternative to data projection for exploratory pur-
poses [33] for selecting outlier samples based on machine
learning rather than on projective mappings of data distri-
butions.
Discussion
In this study data-driven models, which highly depend on
the distribution of data within and across classes, were
considered. The cut-off point on the size of gene signature
selected was determined independently for each model,
based on its maximum performance on the independent
test-set. Even though the ranking of algorithms tested var-
ied between data sets, the main focus was on methodolog-
ical aspects of evaluation so that the points addressed
would remain valid for other data sets and algorithms.
More specifically, the examined approaches were applied
in three different data sets of gradual difficulty as a first
attempt to understand the various CV approaches and
form the basis of as an objective as possible algorithmic
evaluation scheme. The BC data set, which had the less
well defined classes, and its independent test-set was used
as a pilot in the evaluation process. Each of the methods
examined was pushed to perform its best level on the
independent test-set of the pilot data set, by appropriately
fine tuning its parameters. Then, using exactly the same set
of parameters, method performance was assessed, using
various metrics in two additional data sets, along of
course with the pilot one. Using such an approach we
aimed in assessing the sensitivity of each method in vari-
ous data sets or different biomedical experimental scenar-
ios. This approach revealed that RFE-RR and RFE-LSSVM
for instance, highly depend on the data set by producing
diverse and contradictory results along the different com-
putational scenarios presented.
Three different evaluation schemes were used. The maxi-
mum accuracy scheme, tested on both CV and independ-
ent test-sets, presented optimistic results for most
algorithms and all data sets considered. Such results can
be misleading and induce severe bias on the accuracy esti-
mates for predictors, which are far away from the actual
potential of each algorithm on correctly classifying new
unseen cases. The use of such schemes should be avoided
and the average accuracy scheme should be used instead.
Following these guidelines, the performance of all meth-
ods was assessed with a 10-fold evaluation process on the
specific number of genes pointed by the independent test-
set evaluation. This strategy aimed in revealing the con-
sistency of each method in deriving a gene signature with
high prediction accuracy, either on per run or per patient
basis. The former assessed method sensitivity on perturba-
tions of the test-set, while the later addressed sensitivity
on the training set. This evaluation scenario revealed that
the use of a stable independent test-set along with a 10-
fold evaluation process (that uses a different training set
per fold) resulted in more stable and less variant method
performance, than a standard 10-fold CV process. This
result was verified in all three data sets on the per-run
basis, while on the per-patient basis it was verified for two
Table 11: Average performance measures on the Van't Veer et al. [23] (breast cancer) data set after removing samples suspected for 
measurement noise.
Filter Method Wrapper Methods Hybrid Methods
Criterion Fisher's Ratio RFE LNW-GD RFE-SVM RFE-LSSVM RFE-RR RFE-FLDA REF-LNW1 REF-LNW2 RFE-FSVs-7DK
Number of Genes 61 22 32 45 7 28 44 64 73
Per Subject 
Acc(P)-CV
0.80 0.71 0.69 0.76 0.59 0.65 0.74 0.88 0.78
Per Subject 
Acc(P)-Test
0.68 0.74 0.62 0.68 0.68 0.64 0.77 0.69 0.76
Per Run Acc(R)-
CV
0.74 0.63 0.62 0.65 0.55 0.576 0.69 0.74 0.70
Per Run Test 
Acc(R)-Test
0.68 0.74 0.62 0.68 0.68 0.641 0.77 0.69 0.76
Per Run All 
Acc(R)-Overall
0.69 0.71 0.62 0.67 0.65 0.625 0.74 0.70 0.74
All measures are significantly increased compared to those of Table 7 with the removal of only a few samples.BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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data sets (BC and CC). We found that complementing a
stable test-set with a varying one along a 10-fold CV proc-
ess is a less unbiased estimator of method performance on
the initial independent test-set than a standard 10-fold CV
process.
Using the per-patient approach we identified outlier sam-
ples, which usually resulted in an under-estimation of
method performance, while stability index was used to
access method consistency along the iterative 10-fold CV-
process. Such an index however, should be used with cau-
tion and always in association with the accuracy perform-
ance.
Overall, the wrapper methods expressed large variations
in performance depending on the data set. The filter
method derived good results for all data sets on maximum
performance test, but its performance ranking dropped
when average accuracy testing was considered, especially
for the independent test-set. The hybrid methods pre-
served consistently good results for either maximum or
average performance consideration and for all data sets
tested. Focusing on the average performance results in CV
testing, the filter method was among the highest perform-
ers along with hybrid approaches. On the independent
test-set and the overall testing scheme, which forms the
golden standard for our comparisons, the best performers
always included FSV and other hybrid methods, except in
the last data set where LSSVM yielded relatively high accu-
racy.
It becomes clear that comparison and ranking of algo-
rithms, even on the same data set, should be based on sev-
eral characteristic measures. Furthermore, the relatively
small overlap index raises concerns regarding the poten-
tial influence of the small sample random correlation
effect on the derived signatures and the performance esti-
mates. A reason for such effects is the independent selec-
tion process throughout the iterations for the different
data folds. Under CV, each iteration begins with the max-
imum number of genes and recursively eliminates them
up to the minimum specified size, with its own ranking
scheme driven by the data in the training set. Thus, for a
specific size gene signature, the process for each iteration
may select completely different genes. Such drawbacks of
CV have been highlighted before, suggesting the need for
double CV for meta-parameter selection [34]. For the pur-
pose of gene signature selection, we propose the use of a
nested CV scheme, where all iterations operate in parallel.
At every cut-off stage on the size of gene signature, all
genes could be ranked based on the average of their
weights from all CV iterations, so that the same genes sur-
vive for all iterations. In this way the effect of random cor-
relation between gene-sets and data samples is expected to
be reduced. This scheme, however, remains to be tested in
practice.
Conclusion
The prediction accuracy reported by many studies in the
field of microarray analysis reflect a certain bias due to
either the study design, the analysis method (model
design) or the validation process [35,16]. Most published
comparative studies consider that issue as well as the rank-
ing of algorithms on various data sets. This study has
focused in the evaluation platform of algorithmic per-
formance. The main aim was not to strictly compare algo-
rithms, even though a ranking was attempted as a
byproduct of this work, but rather to address inefficiencies
of evaluation and introduce aspects that may reduce
uncertainty in algorithmic evaluation.
Overall, it is concluded that the use of an independent
test-set is beneficial for estimating a baseline on accuracy
results for all algorithms. The CV scheme by itself induces
certain positive or negative bias depending on the data set
and should be complemented with independent tests.
Nevertheless, most often data sets do not come with a
compatible independent test-set obtained under the same
study criteria. Hence, the isolation of a subset as an inde-
pendent test-set must be considered with caution, since
there is a danger of inducing estimation bias due to alter-
ations in the design of the experiment. Furthermore, to
reduce bias in the estimation of measures, the design of
cross-validation splits should be carefully considered as it
should not alter the entire design of the experiment. In
particular, a stratified scheme for sample selection should
be preferred, so that individual samples can be tested a
sufficient number of times throughout the iterations.
Another concept that has been introduced is the "per-
formance profile", which is a matrix recording accuracy
results over the various iterations (for different CV folds)
of the RFE process and enables the computation of subject
and iteration-specific performance measures for each
algorithm. Based on the performance profile, we consider
case-specific measures to reveal stability of the estimate
over different training sets, as well as frequency measures
on gene selection to address the algorithm's consistency in
selecting the same gene signature under different training
conditions. These issues reveal different aspects of algo-
rithmic performance which could influence their ranking
under a cross-validation strategy.
Besides all these algorithmic considerations and compari-
sons, gene selection should always be interpreted from the
biologists' perspectives. Statistical significance is not
always accompanied by biological relevance, thus knowl-
edge of gene function and biological pathways should
always be taken into account. It seems that a more inte-BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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grated scheme of statistical analysis, combined with statis-
tical as well as biological validation is needed in order to
eliminate any misclassifications and thus could safely
being used in the clinical practice and decision-making.
Methods
Considerations of the Application Field
Even though gene selection initially appears as a standard
paradigm of feature selection, the application domain
entails several aspects that add certain constraints to the
problem [17,36]. In such an application we have to deal
with many problems including the following:
i)  Noise of the data: DNA microarrays provide a vast
amount of data which might contain noise along with
redundant information that needs to be processed in such
a way so that the real valuable and useful information is
finally distilled. This resulting gene signature could then
be used by an expert to search, discover and understand
the hidden biological mechanisms involved in the devel-
opment of cancer.
ii)  Limited number of samples: Most of the microarrays
experiments have few samples because of the cost of the
method and the limited number of cases in a short study
period that adhere to the study protocol. As the number of
variables studied is too large relative to the number of
cases, overfitting can easily occur. A related problem refers
to the small sample random correlation effect, which
essentially allows a small number of features to be ran-
domly correlated with the data, with an increased risk of
getting an irrelevant or random solution,
iii) Random measurement effects on samples: each subject
may be measured with different (unknown) CIs on each
gene expression. Thus, average classification measures
and CIs may not be applicable to individual samples; they
might apply on gene space distributions but not on sub-
ject-specific distributions.
iv) Bias on the design of the study: altering the initial number
of genes or the number of cases, may change the design
conditions of the study. Several studies begin with a
smaller set of genes obtained from oversimplified criteria
and proceed with the proposed gene elimination
approach. However, by coupling different selection meth-
ods at the various stages of recursive elimination, one may
bias algorithmic performance by means of affecting the
initial conditions of recursions.
Taking into consideration the above issues and using the
three experimental scenarios presented before, we address
several concerns regarding algorithmic evaluation and
discuss potential measures for the objective comparison
of gene-selection approaches.
Tested Methods
Gene Selection Approaches
In order to select a specific number of features that reflects
best performance in sample classification, two general
methods exist, namely filter and wrapper methods. Filter
methods directly rank genes according to their signifi-
cance using various statistical measures such as Fisher's
ratio, t-statistics, χ2-statistic, information gain, Pearson's
correlation and many others. The top ranked genes that
yield the highest classification accuracy are then selected
as the final set of markers. Wrapper and/or hybrid (or inte-
grated) methods employ a classifier in order to assess the
importance of genes in decision-making and assign
weights to genes by means of the weights of a classifier
trained on the data set. Subsequently, the lowest weighted
genes are eliminated on the basis of RFE and the process
continues in a recursive manner. In the RFE procedure any
classifier could be potentially used as a weight vector esti-
mator, highlighting the intriguing advantage of an open
and adaptive scheme. The vast majority of methods
employ linear predictors for the specific problem of
marker selection, due to the sparse nature of the feature
space [10]. A fundamental attribute of the "philosophy"
of wrapper methods is that gene weights are re-evaluated
and adjusted dynamically from iteration to iteration,
while in filter approaches gene weights remain fixed.
Another qualitative difference between the two philoso-
phies is that filter methods focus on intrinsic data charac-
teristics neglecting gene interactions, while wrapper
methods focus on gene interactions neglecting intrinsic
data characteristics [19]. Recent studies [26,37] also
addressed the advantages of integrating these quite differ-
ent "philosophies" into a single approach, leading to the
so-called hybrid (or integrated) approaches.
Let v be a particular vector sample of gene values with
class label y. A linear classifier can be seen as a predictor of
the target result y that bases its decision on a weight vector
w in the form of  . In essence, this weight vector
identifies the boundary hyperplane between two classes
of interest. Based on this formulation, we can use primary
characteristics of classifiers used in the various tested
methods to assign feature (gene) weights. SVM [38]
searches for the boundary hyperplane that provides the
best separation distance between classes. It minimizes the
regularized power of the weight vector subject to the con-
dition of correct classification of the training set. Least
squares support vector machines (LSSVM) [39] modify
the above problem into a least squares linear problem.
The ridge regression classifier (RR) uses the classification
error as a regularizing factor on the minimization of the
power of the weight vector [8], whereas Fisher's linear dis-
criminant analysis (FLDA) defines the weight vector as the
ˆ y = ′ wvBMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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direction of the projection line of the m-dimensional data
that best separates the classes of interest according to the
Fisher criterion. The gradient descent linear neuron
(LNW-GD) optimizes the l2 norm of the classification
error proceeding in an iterative way imposed by its gradi-
ent.
The hybrid/integrated methods considered proceed in a
similar iterative manner, but appropriately enrich their
learning process within the wrapper scheme with a filter
criterion. The linear neuron weight (LNW) approach
updates the weight of each individual gene towards the
signed direction of the gradient weighted by a factor that
induces the effect of the Fisher's metric [26,37]. The learn-
ing rate (or update parameter) may be used to control the
importance of the Fisher's metric on the derived gene sig-
nature. Thus, we test two learning rates along with this
method. More specifically, LNW2 uses smaller learning
rate than LNW1, favoring the derivation of more statisti-
cally significant genes and the creation of more compact
classes in the space of surviving features. In a similar
framework, the Fisher's support vectors (FSV) approach
appropriately integrates a variation of the Fisher's ratio
within the weight update scheme of SVMs [26]. By
exploiting the kernel formulation of SVM we can derive
several forms of the boundary hyper-surface. These recur-
sive methods are compared with the baseline filter
method of [9], which uses a variation of Fisher's ratio.
Classification Models
The evaluation of feature selection schemes is often per-
formed in association with a subsequent classification
model [5,34]. In our study, the classifier models used for
testing are obtained from the same pool of methods used
for feature selection. This pool covers a wide variety of
popular models, varying from linear discriminant analysis
and the related ridge regression scheme to neural net-
works and support vector machines, all trainable on the
data distribution. In order to disassociate feature selection
from subsequent classification, we require the maximum
performance of classification on the independent test-set.
Thus, each gene-selection scheme is combined with all
classifiers, optimized and tested through the first scenario
on the independent test-set. The algorithmic parameters
are optimized as to maximize performance on the inde-
pendent test-set scenario, under the additional condition
of correct classification of the training set. The classifier
that achieves the best performance under this test is
selected and used with its fixed parameters in all other
evaluation tests. The algorithmic parameters are fixed
based on the more difficult data set of breast cancer and
are similarly used on all three data sets. This scenario is
close to the operation of a decision support system for the
categorization of new cases, where the classifier is used
with fixed, already optimized parameters. Furthermore,
when comparing algorithmic performance on different
data sets, it is important to preserve the same algorithmic
parameters in order to evaluate the stability of algorithms
under a cross-experiment evaluation scheme. Table 12
summarizes the parameter values used for each approach
in the conducted experiments for either gene selection or
classification.
Definition and Justification of Measures
Let νi denote the measurement vector of the ith individual,
or the ith sample of the data set, with yi denoting its asso-
ciated class label. A classifier C trained on a given data set
D maps an unlabelled instance ν ∈ V to a label y ∈ Y. The
notation C(D, ν) indicates the label assigned to an unla-
belled instance ν ∈ V by a classifier built on data set D. In
k-fold CV, the data set D is randomly divided into k mutu-
ally exclusive subsets (folds) D1,..., Dk of approximately
equal size. The classifier is trained and tested k times; each
time t (t = 1,..., k) is trained on D\Dt = {D-Dt} and tested
on Dt. The "performance profile" is the matrix S of m rows
and n columns, where m is the number of runs (folds) and
n the number of subjects. We define each element Sij as
follows:
where K corresponds to the total number of runs induced
by the CV scenario and δ(.,.) indicates the Dirac delta
function.
Along each row of matrix S we define the cardinality CRi of
row i and the cardinality CPj of column j as the number of
active entries (one or zero) within each row and column,
respectively. Along each row of S  we define the mean
accuracy per CV run:
which assess the model's generalization on the test-set,
while keeping the training set fixed. We can also derive the
confidence interval   for the classification of the test-
ing set Di in this run based on a completely separate train-
ing set. Each run Ri is a split-sample process [16], where
the prediction outcomes for the samples in the testing set
are truly independent Bernoulli trials, so that the deriva-
tion of a binomial confidence interval   is fully justi-
fied. Based on multiple split-sample runs, Michiels et al.
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[18] proposed a strategy for the estimation of CIs on the
true prediction power of a method, by means of a percen-
tile on the empirical distribution of multiple run esti-
mates. In this study, we follow a similar approach for
estimating measure of overall accuracy, considering the
percentile distribution of accuracies either per run or per-
subject. We employ the sample mean and standard devia-
tion of per run accuracies in (3) to model multiple run
estimates and derive measures for the mean prediction
accuracy and its CI over all runs, denoted by the pair (accR,
stdR). Notice that the accuracy measure accRi for the ith run
indicates how well the specific training-test can represent
other (new) cases or samples (used in the testing-set).
Consistently high accuracy for all CV runs (with different
training-sets) indicates good overall prediction power and
generalization ability of the method. Thus, the pair (accR,
stdR) is employed as an index of the algorithmic perform-
ance and stability in its learning and generalization proc-
ess. The 95% confidence interval (CIR) is set to 1.96 times
the standard deviation stdR.
We now turn our attention to measures along the col-
umns of the performance profile S that reveal different
issues of algorithmic performance. In this form, the mean
per-subject accuracy is given by:
We can also derive the confidence interval CIpj for the clas-
sification over all runs of subject Pj. Nevertheless, the
assumption of truly independent Bernoulli trials in the
computation of CI breaks down, due to some overlap in
the training sets across the runs [18]. Having denoted the
potential of some bias in the computation of CIpj, we
could use it with the due caution [16]. We also emphasize
that such accuracy measures for individuals are highly
dependent on the testing strategy, e.g. the design of the CV
splits, which affects the number of iterations that this
individual is tested for. Individuals that are randomly
selected in the testing subset many times may yield more
trustworthy measures on the per-subject performance of
the algorithm, as well as tighter bounds on the CIs of accu-
racy. Individuals that are tested only a few times result in
wider CIs, implying that they may influence the predic-
tion of the overall algorithmic performance either in a
positive or negative trend due to the small set random cor-
relation effect. Such samples should be removed from the
process of algorithmic evaluation. In our study we exclude
subjects (samples) that have been tested less than ten
times within the CV procedure. Similarly, per-subject
measures may also be used to identify and clean up the
data from irrelevant samples or samples highly affected by
measurement noise.
The accuracy measure for each subject indicates how well
this tested sample fits the model developed by the training
process. In essence, high accuracy achieved for all CV runs
indicates that the specific sample fits well to the decision
space defined by all other samples. Consistently high
accuracy of the algorithm for all tested samples indicates
good and stable prediction characteristics. Thus, the mean
accuracy accp over all tested samples/subjects may be used
as an index of the prediction power of an algorithm, sim-
ilar to the overall accuracy per runs. The standard devia-
tion  stdp  of the per-subject accuracies over all tested
samples is a measure of algorithmic stability on perturba-
tions of the training and/or testing sets. For that reason,
acc
CPj
S Pi j
i
m
j =
= ∑
1
1
(3)
Table 12: Parameters used for all methods employed; parameters were selected in a way such that best performance was achieved on 
the test-set.
Method Name Weight Assignment 
Classifier
Accuracy Measure 
Classifier
Parameters Used for 
feature selection
Parameters Used for 
Classification
RFE-SVM SVM SVM C = 100 LK†, C = 100
RFE-LNW-GD LNW-GD SVM μ = 10-3, Epochs = 500 LK†, C = 100
RFE-LSSVM LSSVM LSSVM γ = 0.1 LK, γ = 0.1
RFE-RR RR SVM a = 10-1 LK†, C = 1
RFE-FLDA FLDA SVM LK†, C = 100
RFE-LNW1 LNW SVM μ = 10-2 Epochs* LK†, C = 100
RFE-LNW2 LNW SVM μ = 10-4 Epochs@ LK†, C = 100
RFE-FSVs-7DK FSV SVM 7DK‡, C = 100 LK†, C = 100
Filter Fisher's Ratio SVM - LK†, C = 100
* Use 3000 epochs as long as the number of surviving genes is larger than 100 and a variant learning rate afterwards [26].
†Linear Kernel, ‡7 degree polynomial kernel
@ Use 300 epochs as long as the number of surviving genes is larger than or equal to 1024 and 500 epochs afterwards.BMC Bioinformatics 2009, 10:53 http://www.biomedcentral.com/1471-2105/10/53
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small standard deviation of per-subject accuracies of an
algorithm indicates robustness to changes of the sample
distributions. As in the previous case, the 95% confidence
interval (CIP) is set to 1.96 times the standard deviation
stdP.
In order to exploit and compare performance statistics on
various testing sets, we compute separately the average
performances per run involving (i) the CV testing subjects,
(ii) the samples in the independent test-set and (iii) the
total set of tested samples.
Consistency index
We use consistency index as a measure to estimate the sta-
bility of algorithms on the gene-selection process. This
measure is based on gene frequencies over the CV itera-
tions, as defined below:
where [F] defines a descent-ordered list of gene frequen-
cies and Fi is the frequency rate of gene i defined as its
number of occurrences (Oi) over the total number of runs
(R). Furthermore, S is the total number of genes in the sig-
nature of each algorithm, defined on the basis of best per-
formance on the independent test-set (Tables 1, 2, 3).
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